S. N. Anavekar

921 total citations
24 papers, 705 citations indexed

About

S. N. Anavekar is a scholar working on Cardiology and Cardiovascular Medicine, Anesthesiology and Pain Medicine and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, S. N. Anavekar has authored 24 papers receiving a total of 705 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Cardiology and Cardiovascular Medicine, 5 papers in Anesthesiology and Pain Medicine and 4 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in S. N. Anavekar's work include Blood Pressure and Hypertension Studies (6 papers), Anesthesia and Sedative Agents (5 papers) and Eicosanoids and Hypertension Pharmacology (3 papers). S. N. Anavekar is often cited by papers focused on Blood Pressure and Hypertension Studies (6 papers), Anesthesia and Sedative Agents (5 papers) and Eicosanoids and Hypertension Pharmacology (3 papers). S. N. Anavekar collaborates with scholars based in Australia and United States. S. N. Anavekar's co-authors include A. E. Doyle, William J. Louis, W. J. Louis, T. O. Morgan, William M. Wardell, J. Sabto, N. Christophidis, Bevyn Jarrott, Maurizio Toscano and A. E. Doyle and has published in prestigious journals such as New England Journal of Medicine, Diabetes Care and CHEST Journal.

In The Last Decade

S. N. Anavekar

24 papers receiving 589 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
S. N. Anavekar Australia 12 317 104 101 83 76 24 705
Robert F. Maronde United States 16 241 0.8× 87 0.8× 73 0.7× 109 1.3× 103 1.4× 54 873
Lennart Andrén Sweden 19 368 1.2× 110 1.1× 129 1.3× 58 0.7× 60 0.8× 45 981
Robert W. Piepho United States 13 218 0.7× 104 1.0× 74 0.7× 76 0.9× 107 1.4× 30 646
Peter C. Rubin United Kingdom 16 258 0.8× 89 0.9× 90 0.9× 78 0.9× 94 1.2× 48 868
James F. Burris United States 16 314 1.0× 138 1.3× 91 0.9× 49 0.6× 116 1.5× 61 710
Michael Davidov United States 19 505 1.6× 119 1.1× 174 1.7× 72 0.9× 77 1.0× 44 872
L. Terzoli Italy 15 572 1.8× 193 1.9× 119 1.2× 55 0.7× 122 1.6× 41 831
Brian N. C. Prichard United Kingdom 13 272 0.9× 112 1.1× 85 0.8× 67 0.8× 64 0.8× 18 542
B. E. Karlberg Sweden 16 286 0.9× 199 1.9× 79 0.8× 71 0.9× 106 1.4× 52 677
Timothy C. Fagan United States 18 381 1.2× 158 1.5× 192 1.9× 117 1.4× 95 1.3× 42 1.0k

Countries citing papers authored by S. N. Anavekar

Since Specialization
Citations

This map shows the geographic impact of S. N. Anavekar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by S. N. Anavekar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites S. N. Anavekar more than expected).

Fields of papers citing papers by S. N. Anavekar

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by S. N. Anavekar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by S. N. Anavekar. The network helps show where S. N. Anavekar may publish in the future.

Co-authorship network of co-authors of S. N. Anavekar

This figure shows the co-authorship network connecting the top 25 collaborators of S. N. Anavekar. A scholar is included among the top collaborators of S. N. Anavekar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with S. N. Anavekar. S. N. Anavekar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Anavekar, S. N., et al.. (2004). Diabetic Pyomyositis. Diabetes Care. 27(7). 1743–1744. 9 indexed citations
2.
Conway, E. L., et al.. (1992). Pharmacokinetic Comparison of a Slow‐Release Clonidine with a Conventional Formulation After Acute and Chronic Administration in Hypertensives. The Journal of Clinical Pharmacology. 32(5). 427–433. 5 indexed citations
3.
Straznicky, Nora E., L. G. Howes, Henry Krum, et al.. (1991). Cardiac risk factor management Experience of an outpatient hypertension clinic. The Medical Journal of Australia. 155(10). 691–700. 3 indexed citations
4.
Anavekar, S. N., L. G. Howes, Bevyn Jarrott, et al.. (1989). Pharmacokinetics and Antihypertensive Effects of Low Dose Clonidine During Chronic Therapy. The Journal of Clinical Pharmacology. 29(4). 321–326. 11 indexed citations
5.
Anavekar, S. N. & A. E. Doyle. (1986). Evaluation of verapamil in the treatment of hypertension.. PubMed. 2(3 Suppl). 90S–99S. 2 indexed citations
6.
Anavekar, S. N., C. E. Barter, W. R. Adam, & A. E. Doyle. (1982). A Double-Blind Comparison of Verapamil and Labetalol in Hypertensive Patients with Coexisting Chronic Obstructive Airways Disease. Journal of Cardiovascular Pharmacology. 4(Supplement 3). S378–S378. 25 indexed citations
7.
Anavekar, S. N., Bevyn Jarrott, Maurizio Toscano, & William J. Louis. (1982). Pharmacokinetic and pharmacodynamic studies of oral clonidine in normotensive subjects. European Journal of Clinical Pharmacology. 23(1). 1–5. 43 indexed citations
8.
Horowitz, John D., et al.. (1981). Comparative Trial of Mexiletine and Lignocaine in the Treatment of Early Ventricular Tachyarrhythmias After Acute Myocardial Infarction. Journal of Cardiovascular Pharmacology. 3(3). 409–419. 24 indexed citations
9.
Anavekar, S. N., et al.. (1981). Glomerulonephritis Secondary to Mixed Polyclonal Cryoglobulinaemia: Response to Immunosuppression and Plasmapheresis. Australian and New Zealand Journal of Medicine. 11(4). 529–533. 1 indexed citations
10.
Wardell, William M., et al.. (1979). Postmarketing Surveillance of New Drugs: I. Review of Objectives and Methodology. The Journal of Clinical Pharmacology. 19(2-3). 85–94. 29 indexed citations
11.
Anavekar, S. N., et al.. (1979). Evaluation of Indapamide in the Treatment of Hypertension. Journal of Cardiovascular Pharmacology. 1(4). 389–394. 22 indexed citations
12.
Wardell, William M., et al.. (1979). Postmarketing Surveillance of New Drugs: II. Case Studies. The Journal of Clinical Pharmacology. 19(4). 169–184. 8 indexed citations
13.
Anavekar, S. N., et al.. (1978). Parotid and whole saliva in the prediction of serum total and free phenytoin concentrations. Clinical Pharmacology & Therapeutics. 24(6). 629–637. 29 indexed citations
14.
Wardell, William M., Mohammed Hassar, & S. N. Anavekar. (1978). The rate of development of new drugs in the United States, 1963 through 1975. Clinical Pharmacology & Therapeutics. 24(2). 133–145. 25 indexed citations
15.
Anavekar, S. N., W. J. Louis, T. O. Morgan, A. E. Doyle, & C. I. Johnston. (1975). The relationship of plasma levels of pindolol in hypertensive patients to effects on blood pressure, plasma renin and plasma noradrenaline levels. Clinical and Experimental Pharmacology and Physiology. 2(3). 203–212. 48 indexed citations
16.
Anavekar, S. N. & C. I. Johnston. (1974). MANAGEMENT OF ACUTE HYPERTENSIVE CRISES WITH CLONIDINE (CATAPRES). The Medical Journal of Australia. 1(21). 829–831. 5 indexed citations
17.
Louis, William J., A. E. Doyle, & S. N. Anavekar. (1974). Plasma Noradrenaline Concentration and Blood Pressure in Essential Hypertension, Phaeochromocytoma and Depression. Clinical Science. 48(s2). 239s–242s. 31 indexed citations
18.
Morgan, T. O., S. N. Anavekar, J. Sabto, W. J. Louis, & A. E. Doyle. (1974). A comparison of beta adrenergic blocking drugs in the treatment of hypertension. Postgraduate Medical Journal. 50(583). 253–259. 84 indexed citations
19.
Louis, William J., et al.. (1973). Sympathetic Activity and Essential Hypertension. Clinical Science. 45(s1). 119s–121s. 3 indexed citations
20.
Louis, William J., A. E. Doyle, & S. N. Anavekar. (1973). Plasma Norepinephrine Levels in Essential Hypertension. New England Journal of Medicine. 288(12). 599–601. 217 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Robert F. Maronde Breakdown of academic impact, for papers by Lennart Andrén Breakdown of academic impact, for papers by Robert W. Piepho Breakdown of academic impact, for papers by Peter C. Rubin Breakdown of academic impact, for papers by James F. Burris Breakdown of academic impact, for papers by Michael Davidov Breakdown of academic impact, for papers by L. Terzoli Breakdown of academic impact, for papers by Brian N. C. Prichard Breakdown of academic impact, for papers by B. E. Karlberg Breakdown of academic impact, for papers by Timothy C. Fagan
Rankless by CCL
2026